Jonathan Ticku: I Had the Opportunity to Give Testimony to the FDA ODAC in Support of Daratumumab for High-Risk Smoldering Myeloma

Jonathan Ticku, Assistant Professor of Oncology at Mayo Clinic and GU Oncology Lead at Mayo Clinic Health System, shared a post on LinkedIn:

“This week I had the opportunity to give testimony to the FDA Oncologic Drugs Advisory Committee (ODAC) in support of daratumumab for high risk smoldering myeloma.

I was able to represent the perspective and challenges of practicing community hematologists and oncologists.

The ODAC voted in favor (6:2) for daratumumab use in high-risk smoldering myeloma, based on the results of the AQUILA study.”